| Patents for C12N 5 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor (182,629) |
|---|
| 05/27/2004 | WO2004044149A2 Method for suppressing immune system response to transplanted tissue or cells |
| 05/27/2004 | WO2004044147A2 Modified dendritic cells |
| 05/27/2004 | WO2004044146A2 Pluripotent cells from monocytes, and methods of making and using pluripotent cells |
| 05/27/2004 | WO2004044145A2 Compositions and methods for enhancing disease resistance in fish |
| 05/27/2004 | WO2004044142A2 Mesenchymal stem cells and methods of use thereof |
| 05/27/2004 | WO2004044137A2 Modified oligomeric compounds and compositions for use in gene modulation |
| 05/27/2004 | WO2004044127A2 Stem cell populations |
| 05/27/2004 | WO2004044003A2 Use of edg2 receptor in an animal model of heart failure |
| 05/27/2004 | WO2004043990A2 Human stem cell materials and methods |
| 05/27/2004 | WO2004043386A2 Molecules preferentially associated with effector t cells and methods of their use |
| 05/27/2004 | WO2004043344A2 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 05/27/2004 | WO2004043338A2 Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
| 05/27/2004 | WO2004043232A2 Methods for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | WO2004030628A9 Adult bone marrow derived stem cells |
| 05/27/2004 | WO2004026254A3 Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
| 05/27/2004 | WO2004009762A3 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof |
| 05/27/2004 | WO2003075655A3 Novel vip3 toxins and methods of use |
| 05/27/2004 | WO2003073996A3 Human schwannoma cell line |
| 05/27/2004 | WO2003059276B1 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof |
| 05/27/2004 | WO2003044183A8 Interleukin-2 gene transferred lymphokine activated killer cells |
| 05/27/2004 | WO2003033685A3 Method of producing human beta cell lines |
| 05/27/2004 | WO2003019142A9 Compositions and methods for detection and regulation of genes associated with ruptured atherosclerotic plaque |
| 05/27/2004 | WO2003015705A3 In situ immunization |
| 05/27/2004 | WO2003004604A3 Phage displayed pdz domain ligands |
| 05/27/2004 | WO2003002155B1 Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies |
| 05/27/2004 | WO2003001249A3 Modulating photoreactivity in a cell |
| 05/27/2004 | WO2002102854A3 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 05/27/2004 | WO2002092827A3 Corona-virus-like particles comprising functionally deleted genomes |
| 05/27/2004 | WO2002085923A3 In vivo incorporation of unnatural amino acids |
| 05/27/2004 | WO2002083188A3 Dense/porous structures for use as bone substitutes |
| 05/27/2004 | WO2002043478A8 Transgenic transchromosomal rodents for making human antibodies |
| 05/27/2004 | WO2001066563A3 T1r taste receptors and genes encoding same |
| 05/27/2004 | WO2000073764A3 Composition and methods for the therapeutic use of an atonal-associated sequence |
| 05/27/2004 | WO1999046281A8 Novel polypeptides and nucleic acids encoding the same |
| 05/27/2004 | WO1999042077A3 Compositions and methods for regulating lymphocyte activation |
| 05/27/2004 | US20040103458 Transgenic legume with increased proanthocyanidins (PA) concentrations for use as animal feed; decreased gastointestinal bloating |
| 05/27/2004 | US20040103455 Comprises nucleotide sequences coding insecticidal protein for generation and propagation of insect resistant plants; biological pest control |
| 05/27/2004 | US20040103454 Transgenic plants containing molecular decoys that alter protein content therein |
| 05/27/2004 | US20040103453 Lipoxygenase genes, promoters, transit peptides and proteins thereof |
| 05/27/2004 | US20040103448 Using rodent animal model to monitor effectivenes of cell proliferation, viabilty and differentiation inhibitors |
| 05/27/2004 | US20040102612 For diagnosing/treating/preventing disorders; microarrays; drugs; quantitative analysis of toxicity; genetic engineering |
| 05/27/2004 | US20040102407 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
| 05/27/2004 | US20040102405 Using compounds comprising oligonucleotides targeted to nucleic acid encoding squalene synthase; for diagnosis and treatment of disease associated with expression of squalene synthase; cardiovascular disorders, atherosclerosis |
| 05/27/2004 | US20040102404 Modulation of KU86 expression |
| 05/27/2004 | US20040102403 Using compounds comprising oligonucleotides targeted to fibrillarin; for diagnosis and treatment of disease associated with expression of fibrillarin; proliferative disorders, cancer |
| 05/27/2004 | US20040102401 Using compounds comprising oligonucleotides targeted to nucleic acid encoding jagged 1; for diagnosis and treatment of disease associated with expression of jagged 1; developmental disorders, cancer |
| 05/27/2004 | US20040102399 Using compounds comprising oligonucleotides targeted to nucleic acid encoding hypothetical protein 669; for diagnosis and treatment of disease associated with expression of hypothetical protein 669; metabolic disorders |
| 05/27/2004 | US20040102398 Using compounds comprising oligonucleotides targeted to nucleic acid encoding B7H; for diagnosis and treatment of disease associated with expression of B7H; autoimmune diseases |
| 05/27/2004 | US20040102390 Modulation of Notch3 expression |
| 05/27/2004 | US20040102379 Fibroblast growth factor homologous factors (FHFs) and methods of use |
| 05/27/2004 | US20040102373 Protein-induced morphogenesis |
| 05/27/2004 | US20040102372 Therapeutic antiangiogenic compositions and methods |
| 05/27/2004 | US20040102349 Textiles, hard surfaces; storage stability |
| 05/27/2004 | US20040101965 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 05/27/2004 | US20040101962 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 05/27/2004 | US20040101961 Insect cell primary culture medium, extracellular matrix, and process of preparing an insect culture cell line in a short period of time using the medium and matrix |
| 05/27/2004 | US20040101960 Comprises a soft/setting matrix and living cells; can be injected minimally invasively |
| 05/27/2004 | US20040101959 For correcting cosmetic/aesthetic/degenerative defects in skin/bone/soft tissue |
| 05/27/2004 | US20040101958 Method for sterilizing bioactive materials |
| 05/27/2004 | US20040101955 Roller bottle |
| 05/27/2004 | US20040101940 Identification of a new cytotoxic activity from the ink of aplysia punctata |
| 05/27/2004 | US20040101931 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 05/27/2004 | US20040101929 Comprises transgenic yellow grouper brain cell expressing immunoglobulin complex which prevents viral infection in teleost farms; animal husbandry and veterinary medicine |
| 05/27/2004 | US20040101928 Transforming escherichia with humicola nucleotide sequences coding lipase for use in preparation of detergents and baking materials |
| 05/27/2004 | US20040101927 Comprises nucleotide sequences coding polypeptides for diagnosis, prognosis, prevention and treatment of neurodegenerative and cancer disorders |
| 05/27/2004 | US20040101888 Vector system used in screening active substances |
| 05/27/2004 | US20040101882 Secreted proteins |
| 05/27/2004 | US20040101865 Comprises nucleotide sequences coding polypeptides associated with biosynthesis and metabolism of acetyl-CoA for preparing food, feed, cosmetics and pharmaceutical agents |
| 05/27/2004 | US20040101853 Modulation of STAT2 expression |
| 05/27/2004 | US20040101833 Human TREK2, a stretch- and arachidonic acid-sensitive K+ channel activated by inhalational anesthetics and riluzole |
| 05/27/2004 | US20040101831 Monoclonal antibodies to human immunodeficiency virus and uses thereof |
| 05/27/2004 | US20040101819 Self-assembled muscle-powered microdevices |
| 05/27/2004 | US20040101583 Antitumor agent |
| 05/27/2004 | US20040101536 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group B streptococcal carbohydrates |
| 05/27/2004 | US20040101529 Regulation of human serine-threonine protein kinase |
| 05/27/2004 | US20040101526 Bonding integrins and thrombospondin; artificial skin |
| 05/27/2004 | US20040101522 Transduced neoplastic cell preparations able to express T-cell costimulatory molecules B7.1, ICAM-1, and LFA-3 and induce immunostimulatory prophylactic and therapeutic anti-tumor effects in-vivo |
| 05/27/2004 | US20040101519 Cell proliferation; tissue engineering; screening, detection of antigens; immunitherapy; development of vaccine; antitumor, anticancer agents |
| 05/27/2004 | US20040101517 Central nervous system diosrders; Alzheimer's disease; Parkinson's disease; regeneration normal endothelial function; applying oxidation stresses to cells; angiotensin receptor antagonist |
| 05/27/2004 | US20040101509 Chemokine mutants in the treatment of multiple sclerosis |
| 05/27/2004 | US20040099998 Method for manufacturing sintered compact, sintered compact manufactured by the method and cell culture base formed from the sintered compact |
| 05/27/2004 | DE10253066A1 Tissue substitute, useful for repairing lesions, e.g. in cardiac muscle, also for production of e.g. cytokines, comprises preformed three-dimensional tissue grown from suspension culture |
| 05/27/2004 | DE10147638B4 Leukozyten-Inaktivierungs-Modul (LIM) Leukocyte inactivation module (LIM) |
| 05/27/2004 | CA2505807A1 Dna sequences from tcd genomic region of photorhabdus luminescens |
| 05/27/2004 | CA2505551A1 Highly permissive cell lines for hepatitis c virus replication |
| 05/27/2004 | CA2505546A1 Molecules preferentially associated with effector t cells and methods of their use |
| 05/27/2004 | CA2505409A1 Cultivation of hair inductive cells |
| 05/27/2004 | CA2505403A1 Modified dendritic cells |
| 05/27/2004 | CA2505394A1 Human stem cell materials and methods |
| 05/27/2004 | CA2505251A1 Mesenchymal stem cells and methods of use thereof |
| 05/27/2004 | CA2505197A1 Use of edg2 receptor in an animal model of heart failure |
| 05/27/2004 | CA2504903A1 Method for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | CA2504818A1 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 05/27/2004 | CA2502490A1 Transgenic ungulates having reduced prion protein activity and uses thereof |
| 05/27/2004 | CA2492103A1 Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
| 05/26/2004 | EP1421957A1 Treatment of tissue degeneration and replacement of tissue with undifferentiated mesenchymal cells |
| 05/26/2004 | EP1421952A1 Myocardial cell apoptosis inhibitors |
| 05/26/2004 | EP1421947A1 p53 vaccine |
| 05/26/2004 | EP1421539A2 Stabilized proteins with engineered disulfide bonds |
| 05/26/2004 | EP1421391A2 Sodium channel regulators and modulators |